The new pancreatic cancer drug Onivyde is expected to be listed on the insurance benefit.

According to the industry, Servier recently concluded a negotiation with the NHIS for the listing of Onivyde(Irinotecan HCl). As a result, it is expected that new insurance benefits will be available in pancreatic cancer treatment.

Onivyde is eligible for the benefit if it passes the final procedure, the Health Insurance Policy Committee. It is the first achievement in about four years since domestic approval was made in August 2017. The drug has passed the DC of major medical institutions, including Samsung Medical Center, Seoul National University Hospital, Seoul St. Mary's Hospital, Asan Medical